Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tips.2020.07.003 http://scihub22266oqcxt.onion/10.1016/j.tips.2020.07.003 32711925!7359808!32711925     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Trends+Pharmacol+Sci 2020 ; 41 (9): 598-610 Nephropedia Template TP {{tp|p=32711925|t=2020. Can Activation of NRF2 Be a Strategy against COVID-19?|pdf=|usr=}}{{32711925}} gab.com Text Can Activation of NRF2 Be a Strategy against COVID-19 JO: Trends Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32711925 #FOAvip Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive presentation. We propose that a multifaceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2) can be deployed against the virus. The strategy provides robust cytoprotection by restoring redox and protein homeostasis, promoting resolution of inflammation, and facilitating repair. NRF2 activators such as sulforaphane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well-documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19. Twit Text FOAVip Can Activation of NRF2 Be a Strategy against COVID-19 ????Trends Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32711925 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32711925 #FOAvip English Wikipedia <ref>{{Cite pmid|32711925}}</ref> Can Activation of NRF2 Be a Strategy against COVID-19? #MMPMID32711925 Cuadrado A; Pajares M; Benito C; Jimenez-Villegas J; Escoll M; Fernandez-Gines R; Garcia Yague AJ; Lastra D; Manda G; Rojo AI; Dinkova-Kostova AT Trends Pharmacol Sci 2020[Sep]; 41 (9): 598-610 PMID32711925show ga Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive presentation. We propose that a multifaceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2) can be deployed against the virus. The strategy provides robust cytoprotection by restoring redox and protein homeostasis, promoting resolution of inflammation, and facilitating repair. NRF2 activators such as sulforaphane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well-documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19. |Anti-Inflammatory Agents/*therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy[MESH] |Cytoprotection[MESH] |Granulocytes/drug effects/virology[MESH] |Homeostasis[MESH] |Humans[MESH] |NF-E2-Related Factor 2/*metabolism[MESH] |Oxidation-Reduction[MESH] |Pandemics[MESH]Can Activation of NRF2 Be a Strategy against COVID-19?(epmc).pdf DeepDyve Pubget Overpricing